Objective-Regulator of G-protein signaling 5 (RGS5) is abundantly expressed in vascular smooth muscle cells (SMCs) and inhibits G-protein signaling by enhancing the guanosine triphosphate-hydrolyzing activity of Gα-subunits. In the present study, we investigated the effects of RGS5 on vascular SMC function in vitro and neointima formation after wire-induced injury in mice and determined the underlying mechanisms. Approach and Results-We found a robust expression of RGS5 in native arteries of C57BL/6 mice and a highly significant downregulation within neointimal lesions 10 and 21 days after vascular injury as assessed by quantitative polymerase chain reaction, immunoblotting, and immunohistochemistry. In vitro, RGS5 was found significantly downregulated after mitogenic stimulation of human coronary artery SMCs. To restore RGS5 levels, SMCs were transduced with adenoviral vectors encoding wild-type RGS5 or a nondegradable mutant. RGS5-WT and, even more prominently, the C2A-RGS5 mutant prevented SMC proliferation and migration. In contrast, the siRNA-mediated knockdown of RGS5 significantly augmented SMC proliferation. Following overexpression of RGS5, fluorescence-activated cell sorting analysis of propidium iodide-stained cells indicated cell cycle arrest in G0/G1 phase. Mechanistically, inhibition of the phosphorylation of the extracellular signal-regulated kinase 1/2 and mitogen-activated protein kinase downstream signaling was shown to be responsible for the anti-proliferative effect of RGS5. Following wire-induced injury of the femoral artery in C57BL/6 mice, adenoviral-mediated overexpression of RGS5-WT or C2A-RGS5 significantly reduced SMC proliferation and neointima formation in vivo.
T he proliferation of vascular smooth muscle cells (SMCs) represents a key mechanism for the progression of vascular proliferative diseases, such as atherosclerosis, postangioplasty restenosis, or vein bypass graft failure. 1 Excessive neointimal hyperplasia after percutaneous transluminal angioplasty induces restenosis, which often necessitates a secondary revascularization procedure. 2 During neointima formation, SMCs proliferate in response to mitogenic stimuli and migrate toward the luminal side of the artery. 3 Given the high clinical relevance of vascular proliferative diseases, new and selective treatment strategies can only be based on a detailed understanding of the signaling mechanisms involved in SMC activation. 4, 5 Regulator of G-protein signaling 5 (RGS5) is a member of the family of RGS molecules, which regulate the signal transduction of G-protein-coupled receptors (GPCRs) and G-proteins. 6 In nonactivated cells, G-proteins consist of a guanosine diphosphate-bound Gα protein and its associated Gβγ heterodimer. Activators of GPCRs, such as angiotensin II, induce the exchange of guanosine diphosphate to guanosine triphosphate (GTP) on the Gα subunit, which induces dissociation and further G-protein downstream signaling. 7 This signaling cascade is limited by the intrinsic GTP-hydrolyzing activity of the Gα subunit. RGS5 acts as a GTPase-activating protein of the Gα(q) and Gα(i) subunits and thus effectively suppresses the GPCR-induced downstream signaling of wellknown vasoconstrictors and pro-mitogenic molecules, such as angiotensin II, endothelin-1, norepinephrine, or thrombin. 8 Initially, RGS5 was found to be specifically expressed in the SMCs of the aorta and peripheral arteries and in pericytes. 9, 10 More recent studies in mice lacking RGS5 expression February 2016 have shown that a loss of RGS5 leads to hypertension, vessel hypertrophy, and vascular stiffening and correlates with hyper-responsiveness to angiotensin II, endothelin-1, norepinephrine, and thrombin, suggesting that RGS5 plays a pivotal role in attenuating the effects of the aforementioned vasoconstrictors. 6 Inasmuch as these vasoconstrictors also drive SMC growth, RGS5 may also function as an inhibitor of chronic trophic signals within the artery wall. Moreover, RGS5 expression was downregulated in SMCs of atherosclerotic plaques, and platelet-derived growth factor-BB as one of the most critical mediators of SMC proliferation was shown to acutely repress RGS5 expression in SMCs. 10, 11 RGS5 expression is also tightly controlled on the posttranscriptional level via enhanced degradation through the ubiquitin-dependent N-end rule pathway. The Cys-2 residue at the N-terminus of RGS5 is essential for this degradation, and mutants of RGS5 in which this residue cannot reside at the N-terminus (C2A mutant) are stable and long-lived in vivo because of the lacking degradation. 12, 13 The activity of this pathway is controlled by oxygen levels, reactive oxygen species, nitric oxide, and inflammatory cytokines. Because these mediators are largely perturbed after vascular injury, the N-end rule pathway most likely affects the turnover and expression of RGS5 during vascular remodeling processes.
In apolipoprotein E −/− mice lacking RGS5 expression, atherosclerotic plaque progression was increased, which correlated with a more pronounced endothelial dysfunction and enhanced vascular inflammation through NF-κB activation. 14 In contrast, no systematic data are currently available regarding the effects of RGS5 on SMC proliferation in vitro or on the SMC proliferation during neointimal lesion formation in vivo. Moreover, initial observations in non-human primates have suggested that RGS5 is only expressed in aortic or peripheral artery SMCs but not in coronary artery SMCs as assessed by in situ hybridization. 10 In contrast, we now provide evidence that RGS5 is also abundantly expressed and strongly regulated in human coronary artery SMCs. Our data indicate that RGS5 expression is controlled at multiple levels because mitogenic stimulation reduces RGS5 mRNA expression, and posttranslational RGS5 protein expression is tightly controlled by a high turnover rate and degradation via the N-end rule pathway and proteasomal degradation. We further demonstrate that reconstitution of RGS5 prevents the angiotensin II-induced activation of G-protein signaling, resulting in diminished phosphorylation of the downstream signaling molecules mitogen-activated protein kinase kinase (MEK1) and extracellular signal-regulated kinase (ERK1/2). Reconstitution of downregulated RGS5 levels prevents SMC proliferation after mitogenic stimulation in vitro and neointima formation in a mouse model of wire-induced vascular injury in vivo. These data conclusively show that the tightly and multilevel redundantly controlled downregulation of RGS5 represents an important prerequisite for the proliferative response of SMCs following vascular injury and that the reconstitution of RGS5 expression levels is sufficient to prevent negative vascular remodeling processes.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

RGS5 mRNA Expression Levels in SMCs In Vitro and in Neointimal Lesions In Vivo
To evaluate RGS5 expression levels in an in vivo model of neointima formation, we performed wire-induced injury of murine femoral arteries and analyzed RGS5 expression levels at different time points thereafter. As indicated by co-staining for α-smooth muscle actin and Ki-67, the proliferating cells in the neointimal lesions at 10 and 21 days after injury almost exclusively represent proliferating SMCs ( Figure 1A , upper 2 panels). RGS5 expression could be located in the medial SMCs of native, uninjured mouse femoral arteries, and compared with uninjured arteries, the endogenous RGS5 expression was downregulated 10 and 21 days after vascular injury as assessed by immunohistochemistry ( Figure 1A ). Quantitative polymerase chain reaction analysis of RGS5 mRNA expression in the neointimal lesions indicated a significant downregulation of RGS5 10 and 21 days after vascular injury (10 days: 0.37±0.134 vs CTRL, *P<0.05; 21 days: 0.46±0.186 vs CTRL, *P<0.05 n=4; Figure 1B ). Concomitantly, RGS5 protein levels were significantly downregulated 21 days after vascular injury, as quantified by immunoblotting ( Figure 1C ; *P<0.05, n=3).
In vitro, we detected strong RGS5 mRNA and protein expression levels in human coronary artery SMCs. RGS5 mRNA levels were significantly downregulated at 12 and 24 hours after mitogenic stimulation with growth medium as assessed by quantitative polymerase chain reaction ( Figure 1D ; 12 hours: 0.69±0.012 vs serum-free growth medium, *P<0.05; 24 hours: 0.38±0.019 vs serum-free growth medium, *P<0.05, n=4). Significant downregulation of RGS5 protein expression levels was also observed at 12 and 24 hours after mitogenic stimulation with growth medium ( Figure 1E ; *P<0.05, n=3).
RGS5 Protein Expression Is Tightly Controlled by a High Turnover Rate and by Degradation via the N-End Rule Pathway
To reconstitute the downregulated RGS5 levels under mitogenic conditions to assess the impact of RGS5 on SMC function, we transduced SMCs with an adenoviral vector encoding the WT form of RGS5. We detected enhanced expression of the recombinant RGS5-WT at 48 hours post-transduction as assessed by immunoblotting using a specific antibody for the C-terminally added V5-tag ( Figure 2A ). However, the expression of RGS5-WT protein was rather weak and of short duration ( Figure 2B ; downregulation after 72 hours). In contrast, the expression levels of recombinant RGS5-WT were robustly enhanced in the presence of the proteasome inhibitor MG132 (Figure 2A ), indicating that RGS5 expression is tightly controlled by a rapid turnover and posttranslational proteasomal degradation. Therefore, to consistently assess the functional effects of RGS5 reconstitution, we cloned a mutant form of RGS5, in which the C2 residue cannot become N-terminal (C2A mutant) and thus is resistant to N-end rule-dependent proteasomal degradation ( Figure I in the online-only Data Supplement). Indeed, following overexpression, robustly enhanced and stable expression levels of this C2A-RGS5 mutant were detected compared with the recombinant RGS5-WT form ( Figure 2B ). Moreover, expression levels of the recombinant C2A-RGS5 mutant were similar to the expression levels of the recombinant RGS5-WT form in the presence of the proteasome inhibitor MG132, indicating that the C2A mutation effectively prevents the proteasomal degradation of RGS5 ( Figure 2C ). . C, Dilated mouse femoral arteries were excised 21 d after injury, and RGS5 protein expression levels were quantified and compared with uninjured arteries by immunoblotting (*P<0.05, n=3). D, PCR and real-time qPCR using specific primers to detect RGS5 mRNA expression levels were performed in human coronary artery SMCs under basal conditions and at the indicated time points after mitogenic stimulation with growth medium (*P<0.05, n=4). E, Immunoblotting was performed using specific antibodies to evaluate RGS5 protein expression levels in human coronary artery SMCs under basal conditions and at the indicated time points after mitogenic stimulation with growth medium (*P<0.05, n=3). February 2016
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RGS5 Prevents SMC Proliferation and Migration In Vitro
To evaluate the functional effects of RGS5 on the proliferation and migration of SMCs in vitro, human coronary artery SMCs were transduced with adenoviral vectors containing RGS5-WT (Ad-RGS5-WT), the nondegradable mutant (Ad-C2A-RGS5), or a control vector (Ad-empty). At 24 hours after transduction, we detected high and dose-dependent mRNA expression levels of RGS5-WT or C2A-RGS5 in SMCs as assessed by quantitative polymerase chain reaction (n=4; Figure IIA in the online-only Data Supplement).
RGS5-WT overexpression significantly reduced SMC proliferation as assessed by bromodeoxyuridine incorporation after stimulation with growth medium (***P<0.001, n=4). This effect was dose-dependent and significantly stronger after overexpression of the nondegradable mutant C2A-RGS5 (***P<0.001, n=4; Figure 2D ). Furthermore, RGS5-WT overexpression reduced SMC migration significantly as assessed by a modified Boyden chamber assay (**P<0.01; ***P<0.001, n=4; Figure  2E ). However, this effect was already maximal at the lowest viral transfection titers and was not further enhanced after overexpression of the nondegradable mutant C2A-RGS5 ( Figure 2E ). Reconstitution of regulator of G-protein signaling 5 (RGS5) expression represses smooth muscle cell (SMC) proliferation and migration. A-C, Immunoblotting was performed using specific antibodies (V5) to evaluate recombinant RGS5 protein expression levels in human coronary artery SMCs overexpressing the wild-type form (WT), a nondegradable mutant (C2A), or after proteasome inhibition (MG132); representative blots and the respective densitometric analysis (n=3; below) are shown. D, Following adenoviral transduction (MOIs as indicated), SMCs were incubated with growth medium in the presence of bromodeoxyuridine (BrdU). SMC proliferation is expressed as the mean OD450±SEM as determined by anti-BrdU ELISA (**P<0.01, ***P<0.001, n=4). E, Transduced SMCs (MOI=120) were added to the upper side of gelatin-coated tissue culture inserts and allowed to migrate for 6 h in the presence or absence of growth medium in the lower chamber. After removing the cells from the upper compartment of the inserts, the amount of migrated cells was quantified by WST-1 assay (n=4; **P<0.01, ***P<0.001). F, Following the knockdown of RGS5 using specific si-RNA or the indicated controls, SMC proliferation was analyzed by BrdU assay under basal conditions and after incubation in growth medium (***P<0.001, n=4). GM indicates growth medium; MOCK, an untransfected control; MOI, multiplicity of infection; and WST, water-soluble tetrazolium salt.
Then, we performed successful knockdown of RGS5 in SMCs using specific siRNA ( Figure IIB in the online-only Data Supplement). Following siRNA-mediated knockdown, SMC proliferation was significantly increased as assessed by bromodeoxyuridine incorporation (***P<0.001, n=3; Figure 2F ). Following RGS5 knockdown, SMC proliferation also increased significantly already under basal conditions, indicating that RGS5 may also be involved in the control of SMC function under nonstimulated conditions (***P<0.001, n=3; Figure 2F ).
In contrast, overexpression of RGS5 had no effect on apoptosis of SMC, as assessed by a cell death detection ELISA (P=ns; n=4; Figure III in the online-only Data Supplement).
RGS5 Prevents Cell Cycle Entry/ Progression in G0/G1 Phase
To further elucidate the mechanisms responsible for the antiproliferative effect of RGS5, we determined cell cycle progression and the expression of cell cycle-regulating proteins following overexpression or knockdown of RGS5. To achieve strong and constant expression levels and to assure robust inhibition of proliferation, we used the nondegradable mutant C2A-RGS5. As determined by fluorescence-activated cell sorting analysis of propidium iodide-stained cells, C2A-RGS5 overexpression (multiplicity of infection [MOI]=120) prevented cell cycle entry/progression in G0/G1 phase, indicating that RGS5 interferes with very early processes of cell cycle entry/progression (*P<0.05, n=4; Figure 3A and 3B). RGS5 overexpression resulted in decreased protein levels of cyclin D1, CDK1, and proliferating cell nuclear antigen, which are essential for progression through G0/G1 phase, as assessed by immunoblotting. An arrest in G0/G1 phase was also confirmed by the lack of hyper-phosphorylation of the retinoblastoma gene product ( Figure 3C ). The concerted prevention of the upregulation/activation of molecules controlling cell cycle entry suggests that RGS5 may not affect the expression or function of a single cell cycle regulatory protein but rather may interfere with upstream signaling mechanisms that orchestrate early cell cycle entry.
RGS5 Inhibits Activation of MEK/ERK Signaling
Because the MEK/ERK signaling pathway is essential for cell cycle entry and is described to be regulated by the RGS-protein family, we focused on the effects of RGS5 on the G-protein receptor-induced activation of this signaling pathway. The stable reconstitution of RGS5-WT and of C2A-RGS5 (MOI=120) effectively prevented angiotensin II-induced phosphorylation of ERK to the same extent as a specific MEK1 inhibitor (PD98059; Figure 4A and 4B). Furthermore, the simultaneous overexpression of a constitutive active mutant of MEK1 (MEK DD ) fully restored ERK phosphorylation ( Figure 4B ) and completely reversed the growth inhibitory effect of RGS5 (***P<0.001, n=4; Figure 4C ). Comparable results were seen after stimulation with growth medium instead of angiotensin II ( Figure IV in the online-only Data Supplement). These data indicate that RGS5 acts as a GTPase-activating protein specific to Gα(q) and Gα(i) that prevents the GPCR-dependent activation of the MEK/ERK signaling pathway and that the RGS5-induced inhibition of MEK/ERK signaling is largely responsible for the anti-proliferative properties of RGS5.
RGS5 Overexpression Prevents Proliferation of Neointimal SMCs Following Vascular Injury
To determine whether the in vitro results regarding the antiproliferative effects of RGS5 reconstitution in SMCs are reproducible in vivo, we performed a wire-induced inury of the femoral artery in C57BL/6 mice. The administration of adenoviral vectors was performed extraluminally to the dilated artery in a thermosensitive and self-degrading Pluronic F-127 gel. Successful transduction and effective expression of recombinant RGS5 in medial cells were demonstrated by immunohistochemistry 4 days after injury ( Figure 5A ) and by Western blot analysis 7 days after injury ( Figure 5B ). In support of the in vitro observations, overexpression of RGS5-WT or C2A-RGS5 resulted in reduced ERK phosphorylation 7 days after injury ( Figure 5B ). The arteries were harvested 21 days after injury, and the proliferation of neointimal cells was significantly reduced after infection with Ad-RGS5-WT compared with vessels infected with the control vector alone, as assessed by the evaluation of the number of proliferating cell nuclear antigen-positive cells/all cells (10.4%±0.5% vs 7.07%±0.67%; *P<0.05, n=6). The reduction of the proliferation of neointimal cells was even more pronounced after application of the nondegradable mutant Ad-C2A-RGS5 (10.4%±0.5% vs 5.87%±0.41%; *P<0.05, n=6; Figure 5C and 5D).
RGS5 Overexpression Prevents Neointimal Lesion Formation and Luminal Stenosis
To evaluate the effect of RGS5 on neointimal lesion formation and luminal stenosis after vascular injury, mouse femoral arteries were excised 21 days after dilation, and morphometric analysis was performed. The administration of Ad-RGS5-WT resulted in a significant reduction in the neointima/media ratio, neointimal lesion size, medial size, and luminal stenosis but significantly increased the remaining lumen of injured vessels (****P<0.0001, n=6; Figure 6A and 6B). Similar to its effects in vitro and on SMC proliferation in vivo, there was a trend towards an even more pronounced effect of the nondegradable mutant C2A-RGS5 on the reduction of neointimal lesion formation 21 days after vascular injury, which, however, just missed statistical significance (luminal stenosis P=0.052, n=6; Figure 6A and 6B).
C2A-RGS5 Overexpression Improves Re-Endothelialization
Following wire-induced injury, re-endothelialization of the dilated arteries was primarily complete 21 days after wire injury, and no differences were observed between the treatment groups (Figure 6C and 6D ). Furthermore, early endothelial recovery was assessed by en face microscopy 5 days after electric injury of the carotid artery. At that time point, overexpression of Ad-RGS5-WT did not show a significant effect on re-endothelialization (P<ns, n=6). In contrast, endothelial recovery was slightly enhanced after application of the nondegradable mutant C2A-RGS5 (*P<0.05, n=6; Figure 6E and 6F).
Discussion
G-protein-coupled signaling pathways and ERK activation are known to be of paramount importance for the phenotypic plasticity of SMCs. 15 Extracellular stimuli, such as hormones, neurotransmitters, and chemokines, exert their effects on SMCs by binding to GPCRs. RGS5 antagonizes the G-proteininduced signal transduction by its intrinsic GTP-hydrolyzing activity of the Gα(q) and Gα(i) subunits and thus modulates the subsequent signaling and cellular processes. However, the role of RGS5 in the response of SMC to acute vascular injury or during vascular remodeling remains insufficiently defined. In this study, we provide evidence that RGS5 is abundantly expressed in human coronary artery SMCs and that its expression is downregulated in both proliferating SMCs in vitro and in a model of neointima formation in vivo. The reconstitution of RGS5 expression levels prevents the activation of the MEK/ERK signaling cascade, which is essential for the induction of cell cycle entry. The reconstitution of RGS5 results in the downregulation of cyclin D1, proliferating cell nuclear antigen, and CDK1 and prevents the G0/G1/S phase transition of proliferating SMCs. RGS5 overexpression not only significantly reduces SMC proliferation in vitro but also is effective in attenuating SMC proliferation and neointima formation in vivo following wire-induced vascular injury. RGS5 is known to be expressed in endothelial cells, SMCs, and pericytes of the vasculature. 16, 17 However, mice lacking RGS5 expression are viable and do not exhibit developmental defects or defects in vasculogenesis. 18 In contrast, RGS5 deletion results in accelerated atherosclerotic lesion progression in apolipoprotein E −/− mice related to endothelial dysfunction because of higher rates of apoptotic endothelial cells and macrophages within the lesions. 14 These data suggest a protective role of RGS5 in endothelial cells; however, the effect of RGS5 on SMC function during vascular remodeling remains to be defined.
Our data now indicate that RGS5 is highly expressed in differentiated SMCs and that RGS5 expression is tightly A and B , After transduction of SMCs with the indicated adenoviral constructs (MOI=120; MEK DD represents a constitutive active MEK mutant) or incubation with the MEK1 inhibitor PD98059, cells were stimulated with 1 μM angiotensin II for 10 minutes. Then, phosphorylation of ERK1/2 and total levels of ERK1/2 were assessed by immunoblotting using specific antibodies. β-Tubulin served as a loading control. The densitometric analysis of the respective immunoblots is shown in the right panel. C, After transduction of SMCs with the indicated adenoviral constructs (MOI=120), cells were stimulated with 1 μM angiotensin II, and bromodeoxyuridine (BrdU) incorporation was determined after 24 h by anti-BrdU ELISA (***P<0.001 and ****P<0.0001, n=4). ERK indicates extracellular signal-regulated kinase; MEK1, mitogen-activated protein kinase kinase; MOCK, an untransfected control; MOI, multiplicity of infection; and pERK, phosphorylated ERK.
controlled at multiple levels, including an altered mRNA expression and a rapid turnover and proteasomal degradation. Conclusively, previous studies reported that RGS5 can be regulated at the transcriptional level via platelet-derived growth factor-dependent signaling 17 and at the post-translational level via enhanced N-end rule pathway-mediated proteosomal degradation. 12 Interestingly, these signaling cascades have been shown to be crucially involved in vascular remodeling processes. Thus, the tightly and redundantly controlled regulation of RGS5 expression points toward a prominent role of RGS5 in SMC homeostasis and in SMC responses and adaptions to vascular injury.
In an initial study on non-human primates, Li et al described that RGS5 is downregulated in SMCs of atherosclerotic lesions compared with medial SMCs. However, the same study reported a lack of RGS5 expression in the coronary arteries of these primates as determined by in situ hybridization. 10 In contrast, we found robust RGS5 mRNA and protein expression in human coronary artery SMCs and observed profound downregulation of RGS5 expression in proliferating SMCs in vitro and in vivo. These data indicate that RGS5 may also have a role in the development of coronary artery disease and restenosis after percutaneous coronary intervention. Here, we provide evidence that RGS5 inhibits early cell cycle progression during G0/G1 phase before the cells begin to enter the cell cycle. Therefore, we hypothesize that RGS5 interferes with the upstream signaling that regulates G0/G1 phase entry/progression instead of regulating the specific expression of single, distinct cell cycle regulating molecules. Because we previously demonstrated that ERK activation is essential for the proper cell cycle entry and proliferation of vascular SMCs, 19 we assessed the ability of RGS5 to interfere with this signaling pathway. Indeed, our data clearly show that RGS5 prevents phosphorylation of ERK after mitogenic stimulation and that after rescuing this inhibition by overexpressing a constitutive active MEK-mutant, the growth inhibitory effect of RGS5 is abolished. Thus, the inhibition of MEK/ ERK activation identifies a key mechanism by which RGS5 regulates cell cycle entry and proliferation.
Because GPCRs regulate a wide variety of cellular functions in response to extracellular stimuli, other signaling pathways than the MEK/ERK signaling cascade may also be influenced by RGS5. A study on the effects of RGS5 on blood pressure homeostasis showed that Rho kinase signaling is responsible for the observed elevated blood pressure levels in RGS5-deficient mice. Importantly, these mice also showed characteristics of increased arterial stiffness and medial thickness because of SMC hypertrophy. 6 RGS5 was also recently shown to repress the signaling of sonic hedgehog, a further important mediator of SMC differentiation and function. 7, 20 Moreover, platelet-derived growth factor-induced stimulation of SMC after knockout of the transcription factor cAMP response element modulator resulted in different expression levels of RGS5. 21 Thus, in addition to preventing ERKmediated proliferation and migration, RGS5 also controls other signaling mechanisms, which regulate different functions like differentiation, contraction, or hypertrophy, which may also contribute to the observed in vivo effects.
To more closely resemble the in vivo situation, we exposed the SMCs to growth medium, which contains a mix of fetal calf serum, as well as different growth factors. However, even after this redundant activation of multiple signaling cascades, the inhibition of MEK/ERK signaling by RGS5 was sufficient to prevent SMC proliferation. In conclusion with previous reports, these data indicate that (1) MEK/ERK signaling is a mandatory prerequisite for the cell cycle entry of SMC and that (2) interfering with this pathway, that is, by controlling RGS5 expression levels, is sufficient to prevent SMC proliferation even under redundant SMC migration is a further important component, which contributes to neointima formation. 22 However, data regarding the effects of RGS5 overexpression/reconstitution were lacking. Here we demonstrate that overexpression of RGS5 significantly prevents the migration of human coronary artery SMCs. The prevention of cell migration by RGS5 may thus additionally contribute to reduced lesion formation in vivo. Mechanistically, it has been repeatedly demonstrated that ERK activation plays a crucial role in SMC migration. 23 However, the observed antimigratory effect of RGS5 may also be a rather unspecific and general response to cell cycle arrest because cell cycle inhibition not only prevents cellular proliferation but also modulates numerous cellular functions, such as differentiation, inflammation, and migration. 1 Nevertheless, the specific role of RGS5 in the regulation of cell migration requires further investigation.
Re-endothelialization of vascular lesions is important to prevent an acute thrombotic (re-) occlusion to attenuate the inflammatory response by preventing the continuous adhesion and invasion of circulating cells and to restore the vascular integrity and reactivity via the release of nitric oxide. Moreover, the combination of these effects is sufficient to significantly attenuate exaggerated SMC proliferation and neointima formation. Notably, we detected enhanced endothelial recovery following application of the nondegradable mutant C2A-RGS5. Importantly, previous studies reported a protective effect of RGS5 on endothelial function and endothelial cells survival, leading to increased atherosclerosis in RGS5 −/− mice. 14 In summary, these findings suggest that reconstitution of RGS5 expression levels does not attenuate but rather improves re-endothelialization after vascular injury, adding an important safety aspect to these treatment modalities. However, because of the limitations of the in vivo studies using a small animal model and a different vascular bed (mouse femoral artery), further studies are needed to confirm that the observed mechanisms and effects are also operative and equally important during remodeling processes of human coronary arteries.
Taken together, we describe for the first time and provide cumulative evidence that RGS5 is an important negative regulator of the proliferative and migratory response of SMCs following acute vascular injury. Mechanistically, we demonstrate that the inhibition of MEK/ERK signaling and thus the control of early cell cycle entry is responsible for this effect. Because overexpression of RGS5 was able to prevent SMC proliferation and neointima formation without affecting reendothelialization in a mouse model of vascular injury, RGS5 might represent a promising target for future therapeutic strategies to prevent vascular proliferative diseases.
